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Objectives: Integrase drug resistance monitoring deserves attention because of the increasing number of
patients being treated with integrase strand-transfer inhibitors. Therefore, we evaluated the integrase genotyp-
ing success rate at low-level viraemia (LLV, 51–1000 copies/mL) and resistance in raltegravir-failing patients.
Methods: An integrase genotypic resistance test (GRT) was performed on 1734 HIV-1 samples collected dur-
ing 2006–13. Genotyping success rate was determined according to the following viraemia levels: 51–500,
501–1000, 1001–10000, 10001–100000 and .100000 copies/mL. The reproducibility of integrase GRT was
evaluated in 41 plasma samples processed in duplicate in two reference centres. The relationship between
LLV and resistance prevalence was evaluated in a subset of 120 raltegravir-failing patients.
Results: Overall, the integrase genotyping success rate was 95.7%. For viraemia levels 51– 500 and
501–1000 copies/mL, the rate of success was 82.1% and 94.0%, respectively. GRT was reproducible, producing
sequences with a high similarity and an equal resistance profile regardless of the sequencing centre or viraemia
level. Resistance was detected both at LLV and at viraemia .1000 copies/mL (51–500 copies/mL¼18.2%;
501–1000¼37.5%; 1001 –10 000¼53.7%; 10001–100 000¼30.0%; and .100000¼30.8%). At viraemia
≤500 copies/mL, Q148H/K/R and N155H had the same prevalence (9.1%), while the Y143C/H/R was completely
absent. At early genotyping (within 3 months of raltegravir treatment), Q148H/K/R and N155H mutations
were detected regardless of the viraemia level, while Y143C/H/R was observed only in samples with viraemia
.1000 copies/mL.
Conclusions: Our findings prove the reliability of HIV-1 integrase genotyping and reinforce the concept that this
assay may be useful in the management of failures even at LLV.
Keywords: integrase, HIV-1 genotyping, low-level viraemia, raltegravir, elvitegravir, dolutegravir, INSTI, drug resistance
Introduction
Over the past 6 years, raltegravir, the first approved integrase
strand-transfer inhibitor (INSTI), has taken on an important
role in treating HIV infection, both in antiretroviral-naive and
-experienced patients.1 – 4 Nowadays, with two other available
INSTIs (elvitegravir and the second-generation inhibitor dolutegra-
vir), this drug class has strengthened combined ART (cART).5 – 10
These drugs are suitable for the majority of HIV-1-infected patients
because of their potency and tolerability.
Indeed, beyond raltegravir and dolutegravir,2,9,10 elvitegravir
was recently approved by the US FDA for the treatment of HIV
infection in adults who are already taking or have taken HIV med-
icines.11,12 Moreover, recent evidence demonstrated that INSTIs
might be a suitable alternative in virologically suppressed patients
in whom a regimen modification or simplification is being consid-
ered.3,13,14 Finally, among seven regimens recommended for
treating antiretroviral-naive patients, four contain INSTIs.15
However, raltegravir and elvitegravir have shown a low/inter-
mediate genetic barrier for drug resistance development.3,16 – 19
# The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oup.com
J Antimicrob Chemother
doi:10.1093/jac/dkv029
1 of 9
 Journal of Antimicrobial Chemotherapy Advance Access published February 23, 2015
 by guest on February 25, 2015
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
By contrast, dolutegravir has shown a high genetic barrier to the
development of resistance in vitro and in vivo, in clinical trials,5,10
but few data about the usage of this drug are available in clinical
practice.
Standard-of-care management recommends the use of geno-
typic testing for INSTI resistance for patients with a previous
exposure to this drug class who are starting a new INSTI-based
regimen.15,20 – 22 In drug-naive individuals, an INSTI integrase
genotypic resistance test (GRT) should be performed if INSTI
resistance transmission is a concern.15,20 – 22
In general, GRT is recommended in patients with viraemia
levels .500–1000 copies/mL.15,22
This restriction of GRT mostly derives from the technical diffi-
culty of many laboratories in obtaining consistent results with
samples at low-level viraemia (LLV). However, several findings
now support the use of protease/reverse transcriptase GRT at
LLV,23 – 26 but few data about success and reliability in performing
integrase GRT are currently available.27
Moreover, it is now widely demonstrated that the emergence
of mutations associated with resistance to PIs and reverse tran-
scriptase inhibitors is also found at LLV.25,26,28
This phenomenon has great clinical importance since it has
been associated with an increased risk of virological failure.26,28,29
Mutations at LLV can also occur in patients receiving an INSTI-
containing regimen.29,30
For this reason, integrase resistance monitoring at LLV deserves
particular attention because of the potential future extensive use of
INSTIs. Indeed, particular attention should be addressed to ralte-
gravir and elvitegravir in first-line treatment because of their low/
intermediate genetic barrier to the development of resistance.
In this study, we provide data supporting the reliability and use-
fulness of integrase GRT at viraemia levels ,501–1000 copies/mL
by analysing a large population of HIV-1 patients followed in central
Italy, who underwent integrase GRT in routine clinical practice.
Moreover, we evaluated whether different viraemia levels affect
the detection of integrase resistance in HIV-1 patients who failed
a raltegravir-containing regimen.
Patients and methods
Patients
This retrospective study included 1734 HIV-1 plasma samples with
viraemia values .50 copies/mL that were genotyped over the years
2006–13 in two reference centres in Rome (Italy) for routine clinical pur-
poses. Sample information (date of sampling, final results of sequencing,
nucleotide sequences obtained and mutations found in each sequence),
together with the data of patients for whom genotyping was performed
(i.e. viroimmunological, clinical and therapeutic data), were recorded in
an anonymous database.
HIV-1 RNA viral load
Plasma viraemia was determined as previously described26,31 and samples
were stratified into six groups according to the following viraemia ranks:
51–500, 501–1000, 1001–10000, 10001–100000 and.100000 copies/mL.
HIV-1 integrase sequencing
HIV genotype analysis of the integrase was performed on plasma samples
by using either the ViroSeq HIV-1 Integrase Genotyping System (Celera
Diagnostics, Alameda, CA, USA) or an in-house assay.
As previously described for HIV-1 protease/reverse transcriptase geno-
typing,26 some steps of the ViroSeq HIV-1 integrase module were modified
in order to test HIV-1 integrase sequences also in subjects with LLV. Full
details on the amplification and sequencing procedures are described in
the Supplementary Methods and Figure S1 (available as Supplementary
data at JAC Online).
Subtyping analysis
To define HIV-1 integrase subtypes, sequences were aligned using Clustal
W version 2.132 and compared with reference sequences for major HIV-1
subtypes and circular recombinant forms (CRFs) (available at the Los
Alamos database, http://www.hiv.lanl.gov). Subtypes or CRFs were
assigned by constructing phylogenetic trees using the Neighbour Joining
method. Distances were calculated using MEGA version 5.05 based on
the Kimura two-parameter (K2P) model.33 The reliability of the branching
orders was assessed by bootstrap analysis of 1000 replicates. The tree was
viewed using the graphical user interface FigTree. Subtype classification
was confirmed also by the REGA subtype tool (http://www.bioafrica.net/
rega-genotype/html/subtypinghiv.html) and the COMET subtype tool
(http://comet.retrovirology.lu/). To improve the accuracy of recombinant
and unique forms, RDP3 software (http://web.cbio.uct.ac.za/~darren/rdp.
html) and Splits Tree software (http://en.bio-soft.net/tree/SplitsTree.html)
were used.
Evaluation of genotyping success rate
The genotyping success rate was determined on the overall population
and according to the different viraemia ranks (51–500, 501–1000,
1001–10000, 10001–100000 and .100000 copies/mL), regardless of
the genotyping platform upgrades (equipment, kits and reagents) that
occurred from 2006 to 2013.
Evaluation of cross-contamination and resampling
of HIV-1 integrase genotyping
To investigate the possibility of cross-contamination or sample mix-up
during laboratory procedures, all the HIV-1 integrase sequences obtained
from the 1734 genotypic tests requested were used to construct a phylo-
genetic tree. In particular, among all the sequences (1659 from 1308
patients), 233 were from 85 patients with at least one sequence with con-
textual viraemia ≤1000 copies/mL and at least one sequence with con-
textual viraemia .1000 copies/mL. Therefore, the tree was examined to
confirm that all sequences from each patient formed separate distinct
clusters. Phylogenetic analysis of the HIV-1 integrase sequences was per-
formed by using the K2P model of MEGA version 5.05 with the same para-
meters as described above.33
Evaluation of the reproducibility of HIV-1 integrase
genotyping
The reproducibility of HIV-1 integrase genotyping was evaluated in a sub-
group of 41 plasma samples that were processed in duplicate in two ref-
erence centres in Rome. Eighteen samples had viraemia ≤1000 copies/
mL, while 23 samples had viraemia .1000 copies/mL. The mean genetic
distance was used to evaluate the effective reproducibility of HIV-1 inte-
grase genotyping. More specifically, for each pair of sequences obtained
from the same patient, the mean genetic distance was calculated by
using a K2P model.33 A maximum likelihood tree was also constructed
from these sequences to represent the effective relatedness between
the sequences from the same subject. The tree was inferred with the gen-
eralized time reversible (GTR) nucleotide substitution model with gamma
distribution among site rate heterogeneity, a proportion of invariable sites
(GTR+I+D5) and 1000 bootstrap replicates. Paired samples from the
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same subject were identified by a bootstrap support .90%. The analyses
were conducted by using MEGA version 5.05 software. Moreover,
resistance-associated mutations were evaluated and compared for each
couple of sequences.
Evaluation of INSTI resistance
The evaluation of acquired resistance to INSTIs was carried out on a subset
of 182 samples successfully genotyped from 120 patients for whom a GRT
was required because of virological failure on a raltegravir-containing regi-
men (viraemia .50 copies/mL).
Resistance to raltegravir was defined by the presence of at least one
primary resistance mutation among Y143C/H/R, Q148H/K/R and N155H.
The prevalence of INSTI secondary resistance mutations among V54I,
T66A/K/I, L74I/M, E92G/Q/V, T97A, G118R, F121Y, E138A/K, G140A/C/S,
S147G, V151A/I/L, N155S/T, E157Q, G163K/R, S230R, D232N and
R263K34 – 38 was also evaluated. The analyses performed are listed below.
Evaluation of the prevalence of raltegravir resistance
according to different viraemia levels
For this analysis, only one integrase sequence per patient for each viraemia
range was considered to avoid overcalling of resistance mutations. In the
case where more than one sequence per patient was available, the
sequence with the higher number of drug resistance mutations was
retained for the analysis. For sequences without resistance, the last one
was retained. A total of 156 sequences were analysed.
Evaluation of cross-resistance to INSTI according to different
viraemia levels
To evaluate the cross-resistance among INSTIs in the 156 sequences from
patients failing raltegravir, the genotypic susceptibility score (GSS) for ralte-
gravir, elvitegravir and dolutegravir was calculated according to the
Stanford algorithm (http://sierra2.stanford.edu/sierra/servlet/JSierra?action=
algSequenceInput). The GSS was scored as 0 (resistant virus), 0.5 (virus with
intermediate resistance) and 1 (susceptible virus). For each drug, the GSS was
stratified according to the viraemia level score.
Evaluation of the emergence of INSTI resistance according
to the duration of raltegravir treatment
For this analysis, all the 182 sequences were analysed according to the
duration of raltegravir treatment (defined as the time from the first admin-
istration of raltegravir to the time of integrase genotyping). The timepoints
considered were ≤3, 4–6, 7–9, 10–12 and .12 months. The develop-
ment of resistance was evaluated by also considering viraemia levels.
Statistical analysis
Potential differences among the different viraemia groups were evaluated
as follows: (i) for categorical variables, by the x2 test for trend and
Pearson’s x2 test or Fisher’s exact test as appropriate; and (ii) for
continuous variables, by the Mann–Whitney test or Kruskal–Wallis test as
appropriate. In all analyses, P values,0.05 were considered as statistically
significant. The statistical programs used were R open-source software
(version 3.0.2) and SPSS (version 19) for Windowsw (SPSS, Chicago, IL, USA).
Results
Study population
This study included 1734 plasma samples with viraemia
.50 copies/mL from 1358 patients, processed for integrase GRT
in routine clinical practice from 2006 to 2013. Among these 1734
samples, 625 (36.0%), 717 (41.4%) and 392 (22.6%) were obtained
from drug-naive patients, drug-experienced patients never exposed
to INSTIs and raltegravir-experienced patients, respectively. Overall,
viraemia levels of 51–1000 copies/mL accounted for 235 (13.6%)
samples (168 of them with viraemia levels of 51–500 copies/mL)
(Table 1).
Phylogenetic analysis revealed that subtype B was the most
prevalent strain (81.4%) (Table 1). All the other subtypes were pre-
sent with prevalence ,6%; the most prevalent ones were the
recombinant form CRF02_AG (5.8%) and subtype F (4%) (Table 1).
Genotyping success rate
The overall success rate of the genotype amplification and
sequencing was 95.7% and was comparable in the two clinical
centres where the sequences were produced (95.4% versus
96.0%; P¼0.542). The rate of success was 94.0% for samples
with viraemia levels of 501–1000 copies/mL and it was still rele-
vant at 51–500 copies/mL (82.1%) (Table 2).
The additional use of a nested amplification has significantly
improved the overall success rate in samples with LLV. Indeed,
the requirement for the nested amplification significantly
decreased at higher viraemia levels (51–500 copies/mL: 69.4%;
Table 1. Characteristics of plasma samples with HIV RNA .50 copies/mL
at integrase genotypic resistance test
Variables/categories n (%)
Patients, n¼1358
with only one sample 1123 (82.7)
with more than one sample 235 (17.3)
Samples, n¼1734
from drug-naive patients 392 (22.6)
from drug-experienced INSTI-naive patients 717 (41.4)
from raltegravir-experienced patients 625 (36.0)
Subtype
B 1412 (81.4)
CRF02_AG 101 (5.8)
F 69 (4.0)
C 40 (2.3)
BFa 35 (2.0)
G 26 (1.5)
A 17 (1.0)
otherb 34 (2.0)
Samples according to viraemia ranges (copies/mL)
51–500 168 (9.7)
501–1000 67 (3.9)
1001–10000 370 (21.3)
10001–100000 650 (37.5)
.100000 479 (27.6)
INSTI, integrase strand-transfer inhibitor.
aIncluding: CRF_12_BF (17), CRF40_BF (14), 3 CRF46_BF (3), CRF47_BF (1).
bIncluding: CRF01_AE (15); CRF19_cpx (3); D (2); CRF06_cpx (2); CRF09_cpx
(2); JK (1); CRF02_AG, B (1); CRF02_AG,F1,J (1); CRF10_CD (1); CRF14_BG (1);
CRF18_cpx (1); CRF22_01A2 (1); CRF25_cpx (1); CRF31_BC (1); CRF35_AD (1).
Reliability of the integrase HIV-1 resistance test
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500–1000 copies/mL: 55.8%; 1001–10000 copies/mL: 49.6%;
10 001 –100000 copies/mL: 26.4%; and .100000 copies/mL:
17.3%; P,0.001).
A higher success rate was found for sequences from subtype B
than those from non-B subtypes (96.7% versus 91.0%; P,0.001).
This difference in the proportion of successfully performed assays
was mainly due to the presence of several recombinant forms
(success rate: 96.7% for subtype B versus 86.9% for recombinant
forms; P,0.001). By focusing attention on the two most preva-
lent non-B subtypes (F and CRF02_AG), no difference in the suc-
cess rate was found between subtypes F and B (F: 97.1%), while
a significantly lower success rate was found in CRF02_AG
(88.1%) compared with subtype B (P,0.001). By repeating the
success rate analysis in the subsets of samples from drug-naive
patients, drug-experienced patients never exposed to INSTIs
and raltegravir-experienced patients, a similar rate was observed
(data not shown).
Evaluation of cross-contamination and resampling of
HIV-1 integrase genotyping
In order to check for any laboratory contaminations, we performed a
phylogenetic analysis on all the sequences obtained from the 1734
genotypic tests requested (1659 sequences from 1308 patients).
Some 99% (1643/1659) of the sequences had the expected distribu-
tion in the phylogenetic tree. The outgroups of the 16 remaining
sequences may be caused by cross-contamination or mistakes in
sample/sequence attribution.
Among these 1659 sequences, 233 were from 85 patients with at
least one sequence with contextual viraemia ≤1000 copies/mL and
at least one sequence with contextual viraemia .1000 copies/mL.
By evaluating each cluster, we found that sequences belonging
to the same subject showed a high homology (bootstrap value
.90%) in 97.6% of cases (83/85 patients), regardless of LLV.
Three examples of clusters containing sequences from three dis-
tinct patients with different viraemia values and at different time
periods are reported in Figure S2.
Evaluation of the reproducibility of HIV-1 integrase
genotyping
In order to assess the reproducibility of HIV-1 integrase genotyp-
ing, 41 plasma samples were processed in duplicate in two
reference centres in Rome. Overall, a high homology among the
sequences was observed because of the very low genetic distance
found between the HIV-1 integrase sequences from the same
patient [median (IQR): 0.00125 (0–0.00376)]. No significant dif-
ferences were found by comparing the genetic distance among
the sequences with viraemia≤1000 copies/mL and those with vir-
aemia .1000 copies/mL [0.00125 (0–0.00377) versus 0.00125
(0 –0.00251); P¼0.674], thus confirming a high homology of
sequences regardless of the viraemia level. The maximum likeli-
hood tree constructed confirmed the tight relatedness between
sequences from the same sample (Figure S3).
Finally, a complete concordance in the detection of resistance-
associated mutations between the two sequencing centres was
found (data not shown).
Evaluation of raltegravir resistance according to different
viraemia ranges in patients failing raltegravir
The prevalence of raltegravir resistance mutations according to
different viraemia levels was analysed in 156 sequences from a
subgroup of 120 patients failing raltegravir. The characteristics
of this patient subgroup are reported in Table S1. No significant dif-
ferences were found by stratifying the sequences for viraemia
ranges. Overall, the median (IQR) year of genotyping was 2010
(2009– 12) and the proportion of sequences from subtype
B-infected patients was 82.7%.
Fifty-four out of 156 (34.6%) sequences carried at least one pri-
mary raltegravir resistance mutation. Raltegravir resistance preva-
lence is reported in Table 3. N155H was the most prevalent primary
resistance mutation observed (16.0%), followed by Q148H/K/R
(10.9%) and Y143C/H/R (9.6%). Thirteen (8.3%) sequences showed
only secondary resistance-associated mutations (such as T97A,
V151I, G163R and D232N); 3 (23.1%) of these 13 sequences
were present at a viraemia level of 51–500 copies/mL (Table 3).
The prevalence of raltegravir resistance varied according to
viraemia level (Table 3). Interestingly, raltegravir primary resist-
ance was detected even at LLV. In particular, this prevalence
was 18.2% and 37.5% at viraemia levels of 51– 500 and
501–1000 copies/mL, respectively.
An equal prevalence of Q148H/K/R (H¼1, K¼0 and R¼2) and
N155H was found at LLV (viraemia 51 –500 copies/mL: 9.1%;
viraemia 501 –1000 copies/mL: 18.8%), while Y143C/H/R was
absent at LLV.
At a viraemia level of 1001 –10000 copies/mL, the highest
prevalence of raltegravir resistance (53.7%) was found. At this
viraemia level, N155H was the most prevalent mutation (22.0%),
followed by Y143C/H/R (17.1%; C/H/R¼1, C¼2 and R¼4) and
Q148H/K/R (14.6%; H¼4, K¼0 and R¼1).
At viraemia levels .10000 copies/mL, the resistance preva-
lence was 30% (Table 3). Interestingly, at these levels, three
sequences carried both mutations Y143C/H/R and N155H.
Evaluation of INSTI genotypic susceptibility in patients
failing raltegravir
Among the overall 156 sequences analysed, 57.1%, 6.5% and
36.4% showed susceptible, intermediate resistant and resistant
raltegravir GSS, respectively. As expected, by stratifying GSS
according to viraemia level, a high concordance was found
between the proportion of sequences with GSS equal to zero
Table 2. HIV-1 genotyping resistance success rate according to different
viraemia levels
Viraemia range (copies/mL) Success ratea [n (%)]
Overall (n¼1734) 1659 (95.7)
51–500 (n¼168) 138 (82.1)
501–1000 (n¼67) 63 (94.0)
1001–10000 (n¼370) 351 (94.9)
10001–100000 (n¼650) 635 (97.7)
.100000 (n¼479) 472 (98.5)
aThe success of the integrase genotypic resistance test in plasma samples
from HIV-1-infected patients was evaluated on the overall population with
viraemia .50 copies/mL (n¼1734) and by stratifying for viraemia range.
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(Figure 1a) and the proportion of sequences with at least one pri-
mary raltegravir resistance mutation (Table 3). A low proportion of
samples showed intermediate resistant GSS (Figure 1a). These
samples carried only accessory raltegravir resistance mutations
such as T97A, G163R and V151I, whose role in raltegravir suscep-
tibility should be clarified.
Cross-resistance to elvitegravir was found in 28.3% of the overall
sequences; the highest prevalence of resistance was found at the
1001–10000 copies/mL stratum, while lower prevalence values
were found at lower and higher viraemia strata (Figure 1b).
Interestingly, a consistent intermediate resistant elvitegravir GSS
(mainly due to the presence of Y143C/H/R) was found at viraemia
.1000 copies/mL.
Regarding the second-generation INSTI dolutegravir, the pro-
portion of sequences with resistance was very low (intermediate
resistance: 14.7%; high resistance: 1.1%). No significant differ-
ences in the proportion of resistance levels according to viraemia
ranks was observed (Figure 1 panel C).
The only two sequences with considerable resistance to dolute-
gravir (both at viraemia levels .1000 copies/mL) showed muta-
tions Q148K+G140A+E138K and Q148H+G140S+G163G/R,
respectively.
Evaluation of the emergence of INSTI resistance
according to the duration of raltegravir treatment
By stratifying samples according to the time of raltegravir treat-
ment, no significant difference in terms of primary resistance
prevalence was observed [treatment duration in months, n (%):
,3, 12 (40.0); 3–6, 9 (32.1); 6–9, 9 (42.9); 9–12, 7 (36.8); and
.12, 29 (34.5); P¼0.703]. By analysing sequences at early
failure (,3 months of raltegravir treatment, n¼30), 12 (40.0%)
sequences carried at least one primary raltegravir resistance muta-
tion; of these, 5 had a viral load,1000 copies/mL (Figure 2). N155H
was the most prevalent primary raltegravir mutation, found in six
sequences (three of them with viraemia ,1000 copies/mL).
Mutations at position Q148 were found in four sequences (two
of them with viraemia ,1000 copies/mL). Thus, the primary
raltegravir resistance mutations Q148H/R and N155H can be
found starting from the first 3 months of raltegravir treatment
and even at LLV.
Two sequences showed Y143R mutation (both with a viral load
.1000 copies/mL). The remaining 17 (56.7%) sequences did not
show any integrase resistance-associated mutation at early failure
on raltegravir.
Discussion
This study aimed at evaluating the integrase genotyping success
rate even at LLV in a large dataset of samples tested in two clinical
centres in Italy. Our results showed that the genotyping success
rate was 95.7% for the overall population. In particular, this
success rate was very high also for viral load levels below
≤500 copies/mL (82%), reaching 94% at 501–1000 copies/mL
and.94% at.1000 copies/mL. In light of the increasing usage of
INSTIs, recently approved for all categories of HIV-1 patients,11,15,22
these results demonstrate that integrase resistance monitoring
can be performed also at LLV.
In this regard, the ability to easily analyse samples with LLV is
mainly due to the improvement of the amplification step per-
formed in our laboratories. As previously described for protease/
reverse transcriptase genotyping,26 the usage of nested PCR
(especially for samples with LLV) did not significantly affect either
the cost/timing of genotyping or its reliability and reproducibility
at different viraemia levels. Indeed, by analysing the sequences
from 41 plasma samples processed in duplicate in the two refer-
ence centres, a tight relatedness and an identical resistance pro-
file between sequences from the same sample were found even
at viraemia levels ≤1000 copies/mL. Moreover, by evaluating 233
integrase sequences obtained from 85 patients with at least two
GRTs performed at different times and with a contextual viraemia
≤1000 copies/mL and .1000 copies/mL, a very high homology
among sequences from the same patient was observed (97.6%).
Our results provide new details about the performance of inte-
grase genotyping since few data are currently available about this
issue. To et al.27 compared integrase genotyping between
Table 3. Resistance to raltegravir stratified for plasma viraemia range
Viraemia range (copies/mL) n
Samples with at
least one primary
raltegravir
mutation
Samples with
Y143C/H/R
Samples with
Q148H/K/R
Samples
with N155H
Samples with only
secondary
resistance
mutations
n (%) Pa n (%) Pa n (%) Pa n (%) Pa n (%) Pa
Overall range 156 54 (34.6) 0.421 15 (9.6) 0.028 17 (10.9) 0.561 25 (16.0) 0.702 13 (8.3) 0.860
51–500 33 6 (18.2) 0 (0.0) 3 (9.1) 3 (9.1) 3 (9.1)
501–1000 16 6 (37.5) 0 (0.0) 3 (18.8) 3 (18.8) 0 (0.0)
1001–10000 41 22 (53.7) 7 (17.1) 6 (14.6) 9 (22.0) 4 (9.8)
10001–100000 40 12 (30.0) 4b (10.0) 3 (7.5) 7b (17.5) 6 (15.0)
.100000 26 8 (30.8) 4c (15.4) 2 (7.7) 3c (11.5) 0 (0.0)
aPotential differences in the percentage of resistance among the different viraemia ranges were evaluated by the x2 test for trend. P values,0.05 were
considered as statistically significant.
bTwo samples showed N155H+Y143C/H/R (C/H/R¼1 and C¼1).
cOne sample showed N155H+Y143C.
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Figure 1. INSTI genotypic susceptibility scores (GSS) according to viraemia level in samples from patients failing a raltegravir-containing regimen. White,
grey and black bars represent the proportion of sequences with susceptible, intermediate and resistant GSS according to the HIVDB algorithm (http://sierra2.
stanford.edu/sierra/servlet/JSierra?action=algSequenceInput), respectively. (a) Scores for raltegravir. (b) Scores for elvitegravir. (c) Scores for dolutegravir.
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in-house and commercial assays, to illustrate integrase poly-
morphisms in HIV-1 B and non-B subtypes but only in samples
with a viral load .1000 copies/mL. In another study, integrase
genotyping was performed in patients failing raltegravir with
detectable viral loads .20 copies/mL and raltegravir resistance
was evaluated according to viraemia level. Although integrase
resistance was detected even at ,200 copies/mL, the perform-
ance and reproducibility of integrase genotyping according to vir-
aemia level was not mentioned.18
Regarding the evaluation of resistance at raltegravir failure, in
our population the prevalence of raltegravir resistance (defined as
the presence of at least one primary resistance mutation among
Y143C/H/R, Q148H/K/R and N155H) was 34.6%, similar to that
found in the study by Malet et al.,18 performed on 161 patients
failing on raltegravir (28.6%). In contrast, in other studies based
on data from clinical practice, the prevalence of integrase resist-
ance was higher, ranging from 42.8% to 68%.39 – 42
This discrepancy in the prevalence of raltegravir resistance can
probably be explained by heterogeneity in the choice of mutations
considered for the resistance definition, the population analysed
and, most importantly, the time of integrase genotyping during
failure and the viraemia level at GRT.
In our study, the prevalence of raltegravir resistance varied
according to viraemia level. In particular, the highest prevalence
of resistance was observed at viraemia levels of 1001–10000
copies/mL, while resistance was lower at lower and higher viraemia
strata. Similar results were observed by Malet et al.,18 even though
the viraemia stratification used was different. The decline in the
prevalence of resistance observed at the very high viral load strata
might reflect suboptimal medication adherence, with lower drug
resistance selection.
We found that at LLV the prevalence of resistance ranged between
18.2% and 37.5%, with the presence of Q148H/K/R and N155H hav-
ing similar prevalence (9.1% at a viraemia level of 51–500 copies/mL;
18.8% at viraemia 501–1000 copies/mL). Mutations C/H/R at pos-
ition Y143 were not detected at viraemia,1000 copies/mL, underlin-
ing their association with high viral load.
Our GSS data support the hypothesis that cross-resistance
between raltegravir and elvitegravir is also evident at LLV. On
the other hand, resistance to dolutegravir was observed only in
two sequences (1.1%), both at viraemia.1000 copies/mL, carry-
ing Q148H/K plus two accessory mutations (G140A+E138K and
G140S+G163G/R). This mutational pathway is known to confer
reduced susceptibility to dolutegravir.9,43
Analysing the association between the raltegravir primary
resistance and the duration of raltegravir treatment, we found
that Q148H/R (alone or together with the accessory mutation
G140S) and N155H are detected during the first 3 months of ral-
tegravir treatment and even at LLV. This finding suggests the
importance of careful monitoring of resistance at early timepoints
and/or LLV in order to avoid an accumulation of resistance.29
It should be highlighted that the maintenance of raltegravir
pressure on viruses carrying Q148H/K/R or N155H has been asso-
ciated with an accumulation of accessory resistance mutations
(which increase the phenotypic resistance and viral fitness
of resistant viruses) or with the switch of N155H to Q148H/K/R
mutation.16,44 – 46
This study might have some limitations. First, the majority of
the 1734 samples analysed were genotyped from patients
never exposed to INSTI selective pressure. Indeed, even though
these samples were useful to evaluate the performance of inte-
grase genotyping, the reliability of the assay to detect resistance
mutations was tested in a subgroup of 182 samples. This limita-
tion is mainly due to the fact that at the moment the number of
raltegravir failures in clinical practice is very low because of both
the high rates of virological success in raltegravir-treated patients
and the recent introduction of INSTIs in the clinic. Further analyses
with a higher number of samples are warranted to confirm
these data.
A second limitation could be that in our analyses, despite the
overall high success rate, the success rate in samples from
patients infected by non-B subtypes was significantly lower than
in those infected by subtype B (91% versus 96%). This discrepancy
was mainly observed in samples with recombinant forms.
Finally, the resistance at LLV was only quantitatively described,
without any evaluation of its impact on subsequent virological
outcome. This point was outside the primary scope of this article,
yet an analysis was performed on a subset of 18 patients in first-
line regimen for whom a GRT was requested at viraemia levels of
51–1000 copies/mL. Even though this analysis was performed
on a very small population, the probability of reaching viraemia
.1000 copies/mL by 1 year after LLV was significantly higher in
patients with at least one primary raltegravir resistance mutation
than in those without resistance (100% versus 14.9%; P¼0.011;
data not shown). This suggests that early detection of resistance
(when viraemia is still ≤1000 copies/mL) may prevent evolution
towards (i) virological failure with higher viraemia and (ii) the
accumulation of additional mutations, thus affecting the choice
of future therapeutic regimens, as previously proposed.30,47
In conclusion, the INSTI class, with three drugs suitable
for both drug-naive and multi-experienced HIV-1-infected
patients, is an exceptional opportunity for modern cART to
ensure greater chances of virological success. However, this
opportunity should only be grasped in combination with resist-
ance monitoring. The reliability and reproducibility of HIV-1 inte-
grase GRT guarantees the detection of primary resistance
mutations either at early timepoints or at LLV. These findings
may be useful in the management of failures even at LLV to
avoid the accumulation of mutations and cross-resistance
within the INSTI class.
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